4.6 Article

Age Correction in Dementia - Matching to a Healthy Brain

Journal

PLOS ONE
Volume 6, Issue 7, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0022193

Keywords

-

Funding

  1. LIFE - Leipzig Research Center for Civilization Diseases at the University of Leipzig
  2. European Union
  3. European Regional Development Fund (ERFD)
  4. Free State of Saxony
  5. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  6. National Institute on Aging
  7. National Institute of Biomedical Imaging and Bioengineering
  8. Abbott
  9. AstraZeneca AB
  10. Bayer Schering Pharma AG
  11. Bristol-Myers Squibb
  12. Eisai Global Clinical Development
  13. Elan Corporation
  14. Genentech
  15. GE Healthcare
  16. GlaxoSmithKline
  17. Innogenetics
  18. Johnson and Johnson
  19. Eli Lilly and Co.
  20. Medpace
  21. Merck and Co.
  22. Novartis AG
  23. Pfizer
  24. F. Hoffman-La Roche
  25. Schering-Plough
  26. Synarc
  27. Alzheimer's Association
  28. Alzheimer's Drug Discovery Foundation
  29. Northern California Institute for Research and Education
  30. NIH [P30 AG010129, K01 AG030514]
  31. Dana Foundation

Ask authors/readers for more resources

In recent research, many univariate and multivariate approaches have been proposed to improve automatic classification of various dementia syndromes using imaging data. Some of these methods do not provide the possibility to integrate possible confounding variables like age into the statistical evaluation. A similar problem sometimes exists in clinical studies, as it is not always possible to match different clinical groups to each other in all confounding variables, like for example, early-onset (age, 65 years) and late-onset (age >= 65) patients with Alzheimer's disease (AD). Here, we propose a simple method to control for possible effects of confounding variables such as age prior to statistical evaluation of magnetic resonance imaging (MRI) data using support vector machine classification (SVM) or voxel-based morphometry (VBM). We compare SVM results for the classification of 80 AD patients and 79 healthy control subjects based on MRI data with and without prior age correction. Additionally, we compare VBM results for the comparison of three different groups of AD patients differing in age with the same group of control subjects obtained without including age as covariate, with age as covariate or with prior age correction using the proposed method. SVM classification using the proposed method resulted in higher between-group classification accuracy compared to uncorrected data. Further, applying the proposed age correction substantially improved univariate detection of disease-related grey matter atrophy using VBM in AD patients differing in age from control subjects. The results suggest that the approach proposed in this work is generally suited to control for confounding variables such as age in SVM or VBM analyses. Accordingly, the approach might improve and extend the application of these methods in clinical neurosciences.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available